Cytokinetics says potential acquirer walked away [Seeking Alpha]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Seeking Alpha
In 2023, Cytokinetics began having discussions with potential partners regarding its hypertrophic cardiomyopathy drug aficamten. One of those companies expressed interest in acquiring all of Cytokinetics. "The Board was supportive of moving forward on a potential acquisition on substantially the terms the counterparty communicated to us and on terms that we believed were going to be mutually acceptable," Cytokinetics ( CYTK ) said in an SEC 8-K filing. "However, the third party did not move forward with an acquisition of our company at that time. " The company added, "If there had been an actionable proposal in the best interests of shareholders, it would have received support of our Board and would have been executed with support of Management." Shares are up ~7% in Wednesday morning trading. Recommended For You More Trending News Recommended For You More Trending News About CYTK Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.MarketBeat
- Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants [Yahoo! Finance]Yahoo! Finance
- Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese ParticipantsGlobeNewswire
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at B. Riley from $122.00 to $92.00. They now have a "buy" rating on the stock.MarketBeat
CYTK
Earnings
- 5/8/24 - Miss
CYTK
Sec Filings
- 6/17/24 - Form 144
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- CYTK's page on the SEC website